AGM
RETA

Alpine Global Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Alpine Global Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,500
Closed -$354K – 206
2017
Q4 		$354K Buy
12,500
+1,500
+14% +$41.9K 0.08% 97
2017
Q3 		$342K Buy
+11,000
New +$331K 0.1% 133

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Alpine Global Management's RETA Position: Q1 2018 in Review

Alpine Global Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2018, closing a stake of 12,500 shares — an estimated $354K sold.

Alpine Global Management first reported a position in RETA in Q3 2017 and held it in 2 quarters. The position peaked at $354K in Q4 2017. 86 funds tracked by Wall St. Rank hold RETA as of Q1 2018.

  • Alpine Global Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2018 after selling out during the quarter.
  • Alpine Global Management sold 12,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2018, an estimated $354K.
  • Alpine Global Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 2 quarters.
  • Alpine Global Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $354K in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2018.

Based on Alpine Global Management's 13F filing for Q1 2018, filed 16 May 2018.